The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab (pembro), lenvatinib, and chemotherapy in patients (pts) with metastatic non-small cell lung cancer (NSCLC) harbouring a targetable mutation who experienced disease progression on standard tyrosine kinase inhibitors (TKIs).
 
Hoi Wai Chan
No Relationships to Disclose
 
Chris Chun Long Tse
No Relationships to Disclose
 
Yu-Chung Li
Travel, Accommodations, Expenses - World Conference on Lung Cancer
 
Roland Ching-Yu Leung
Travel, Accommodations, Expenses - MSD Oncology; Roche/Genentech
 
Jeffrey Sum Lung Wong
Travel, Accommodations, Expenses - MSD
 
Gin Wai Kwok
No Relationships to Disclose
 
Hoi Lam Li
No Relationships to Disclose
 
Wing Yan Josephine Tsang
No Relationships to Disclose
 
Cho Wing Li
No Relationships to Disclose
 
Jenny WY Lo
No Relationships to Disclose
 
Vikki Tang
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Rina Hui
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Janssen; Lilly; Merck; Merck Sharp & Dohme; Novartis; OncoSec; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck; Merck Sharp & Dohme; Novartis; OncoSec; Pfizer; Roche; Seagen
Research Funding - AstraZeneca (Inst); BMSi (Inst); Corvus Pharmaceuticals (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); OncoSec (Inst); Roche (Inst); Seagen (Inst)
 
Thomas Yau
Honoraria - AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology
Consulting or Advisory Role - Bristol-Myers Squibb
 
James CM Ho
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Merck; MSD; Novartis
Speakers' Bureau - AstraZeneca; Janssen; MSD; Novartis
 
Joanne W Chiu
No Relationships to Disclose